- MGS has opened a 300,000-square-foot manufacturing facility in Richfield, Wisconsin, to support a global pharmaceutical partner’s drug delivery platform.
- The site includes 140,000 square feet of Class 8 cleanrooms and is expected to create 300 new jobs, with full staffing anticipated by early 2027.
MGS, a contract development and manufacturing organization (CDMO), has introduced a new manufacturing facility in Richfield, Wisconsin. The 300,000-square-foot site was developed to support a global pharmaceutical partner’s expanding drug delivery platform and to meet increasing demand for high-volume manufacturing of complex pharmaceutical devices.
The facility includes 140,000 square feet of Class 8 cleanrooms designed for manufacturing, automation, and assembly. According to the company, the site was completed in 22 months from initial discussions to shipped parts. Phase one includes more than 100 injection molding machines, custom automation technology, and automated assembly lines. Phase two is designed to double production capacity to support future product growth. The site is capable of producing hundreds of millions of sub-assemblies annually.
“From day one, every decision was guided by our customer’s needs and the patients they serve. This facility is proof of what’s possible when aligned expertise and a shared vision come together to accelerate life-changing therapies. Our agile structure and financial strength enabled the speed, investment and coordination required to bring this complex project to life on an ambitious timeline.”
Bob Bordignon, senior vice president of sales & marketing at MGS
The Richfield expansion increases MGS’ global footprint to 12 facilities across North America and Europe. The company provides vertically integrated services spanning early-stage design and development, advanced tooling, custom automation, precision medical manufacturing, and assembly. These capabilities are supported by regulatory expertise and are intended to streamline development and contract manufacturing across the product lifecycle.
The new site is expected to create 300 jobs across engineering, production, automation, quality, and mold maintenance, with full staffing anticipated by early 2027. Roles will be open to experienced professionals and those new to the industry. MGS said employees will receive hands-on training and work within a rotating schedule designed to provide flexibility while supporting advanced pharmaceutical device manufacturing operations.
